2023-509079-18-00CompletedPhase 1
Evaluation of Safety, Tolerability, and Pharmacodynamic Effects of Topically Applied SUDO-286 in Psoriasis
Source: EU CTIS (euclinicaltrials.eu) · Last updated 24 Mar 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 29 Apr 2024
- Start date
- 22 Jul 2024
- Lead sponsor
- Sudo Biosciences Limited
- Diseases
- Psoriasis
- EU CT number
- 2023-509079-18-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 15
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fachaerztliche Gemeinschaftspraxis fuer Dermatologie Und Venerologie Allergologie Umweltmedizin Lasermedizin GbR | Blankenfelde-Mahlow | Germany | Completed |
| Dr. Niesmann And Dr. Othlinghaus GbR | Bochum | Germany | Completed |
| Eurofins bioskin GmbH | Hamburg | Germany | Completed |
| Klinische Forschung Schwerin GmbH | Schwerin | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.